Angelo Pirozzi, Medical Oncology Fellow at Humanitas University and Research Fellow at Mayo Clinic (Phoenix), made the following post on X:
”CAR-T cells targeting claudin-18.2 in pretreated advanced PDAC.
- 2 phase I/Ib trials with 24 patients.
- 79% ≥2 previous systemic lines.
- ORR 16.7%.
- DCR 70.8%.
- mPFS 3.3 months.
- mOS 10.0 months.
- mDoR 9.5 months.”
Read further.
Source: Angelo Pirozzi/X